Monoclonal antibody therapies for COVID-19: lessons learned and implications for the development of future products

B Kelley, P De Moor, K Douglas, T Renshaw… - Current Opinion in …, 2022 - Elsevier
Highlights•Multiple companies are authorized to treat COVID-19 patients with monoclonal
antibodies (mAbs).•They were discovered, developed, manufactured, tested, and approved …
被引用次数：23 相关文章

[引用][C] Monoclonal antibody therapies for COVID-19: lessons learned and implications for the development of future products

B Kelley, P De Moor, K Douglas, T Renshaw… - Current Opinion in …, 2022 - cir.nii.ac.jp
Monoclonal antibody therapies for COVID-19: lessons learned and implications for the
development of future products | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ …

Monoclonal antibody therapies for COVID-19: lessons learned and implications for the development of future products.

B Kelley, P De Moor, K Douglas… - Current Opinion in …, 2022 - europepmc.org
Several companies were authorized to treat COVID-19 patients with monoclonal antibodies
within 1–2 years of the start of the pandemic. These products were discovered, developed …

Monoclonal antibody therapies for COVID-19: lessons learned and implications for the development of future products.

B Kelley, P de Moor, K Douglas, T Renshaw… - 2022 - cabidigitallibrary.org
Several companies were authorized to treat COVID-19 patients with monoclonal antibodies
within 1-2 years of the start of the pandemic. These products were discovered, developed …

Monoclonal antibody therapies for COVID-19: lessons learned and implications for the development of future products

B Kelley, P De Moor, K Douglas… - Current opinion in …, 2022 - pubmed.ncbi.nlm.nih.gov
Several companies were authorized to treat COVID-19 patients with monoclonal antibodies
within 1-2 years of the start of the pandemic. These products were discovered, developed …
[HTML] nih.gov

[HTML][HTML] Monoclonal antibody therapies for COVID-19: lessons learned and implications for the development of future products

B Kelley, P De Moor, K Douglas… - Current Opinion in …, 2022 - ncbi.nlm.nih.gov
Several companies were authorized to treat COVID-19 patients with monoclonal antibodies
within 1–2 years of the start of the pandemic. These products were discovered, developed …

Monoclonal antibody therapies for COVID-19: lessons learned and implications for the development of future products.

B Kelley, P De Moor, K Douglas… - Current Opinion in …, 2022 - europepmc.org
Several companies were authorized to treat COVID-19 patients with monoclonal antibodies
within 1-2 years of the start of the pandemic. These products were discovered, developed …

[引用][C] Monoclonal Antibody Therapies for COVID-19: Lessons Learned and Implications for the Development of Future Products

B Kelley, P De Moor, K Douglas, T Renshaw… - 2022